



Express Mail No.: **EV 654 850 846 US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Young et al.

Confirmation No.: 7010

Application No.: 09/724,531

Group Art Unit: 1648

Filed: November 28, 2000

Examiner: Stacy Brown Chen

For: METHODS OF
ADMINISTERING/DOSING ANTI-RSV
ANTIBODIES FOR PROPHYLAXIS AND
TREATMENT

Attorney Docket No.: 10271-021-999
CAM: 209073-999020

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

MAIL STOP RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby invite the Examiner's attention to references **A01 to A18, B01 to B07, and C01 to C23** listed on the attached form entitled "List of References Cited by Applicant." Copies of references **A01 to A03, B01 to B07 and C01 to C23** are enclosed herewith.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

This supplemental information disclosure statement is being filed along with a Request for Continued Examination under 37 C.F.R. §1.114 in connection with the subject application. Pursuant to 37 C.F.R. §1.97(b), Applicants believe that no fee is due in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, please charge the amount any such fee to Jones Day deposit account no. 50-3013.

Respectfully submitted,

Date October 5, 2005



Margaret B. Brivanlou

40,922

(Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939


LIST OF REFERENCES CITED BY APPLICANT
 (Use several sheets if necessary)

ATTY DOCKET NO.

10271-021-999

APPLICATION NO

09/724,531

APPLICANT

Young et al.

FILING DATE

November 28, 2000

GROUP

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	09/724,396	11/28/00	Young et al.			
	A02	10/403,180	03/31/03	Young et al.			
	A03	11/230,593		Tous et al.			9/21/05
	A04	2004/0005323	01/08/04	Brams et al.			
	A05	2004/0005324	01/08/04	Pilkington et al.			
	A06	2004/0076631	04/22/04	Brams et al.			
	A07	2004/0131609	07/08/04	Young et al.			
	A08	2005/0002926	01/06/05	Young et al.			
	A09	2005/0147616	07/07/05	Young et al.			
	A10	4,800,078	01/24/89	Prince et al.			
	A11	5,667,988	09/16/1997	Barbas et al.			
	A12	5,762,905	06/09/98	Burton et al.			
	A13	6,117,980	09/12/00	Gonzalez et al.			
	A14	6,413,771	07/02/02	Brams et al.			
	A15	6,565,888	05/20/03	Tracy et al.			
	A16	6,685,942	02/03/04	Brams et al.			
	A17	6,818,216	11/16/04	Young et al.			
	A18	6,855,493	02/15/05	Young et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUBCLA SS	TRANSLAT ION	YES	NO
	B01	EP 0 699 756 A1	06/03/96	PCT					
	B02	WO 94/06448	03/31/94	PCT					
	B03	WO 96/40252	12/19/96	PCT					
	B04	WO 97/32572	09/12/97	PCT					
	B05	WO 98/33919	08/06/98	PCT					
	B06	WO 01/55217 A	08/02/01	PCT					
	B07	WO 01/64751 A	09/07/01	PCT					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Arbiza et al., "Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus," <i>J. Gen. Virol.</i> 73: 2225-2234 (1992)
C02	Barbas et al., "Selection and evolution of high-affinity human anti-viral antibodies," <i>Trends Biotech.</i> 14(7):230-234 (1996)
C03	Bentley and Rabbits, 1980, "Human immunoglobulin variable region genes-- DNA Sequences of Two V Kappa Genes and a Pseudogene", <i>Nature</i> 288: 730-733
C04	Chamat et al., "Human monoclonal antibodies isolated from spontaneous Epstein-Barr Virus - transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus," <i>J. Infect. Dis.</i> 180:268-277 (1999)
C05	Chanock et al., "Respiratory syncytial virus," <i>Viral Infections of Humans, Epidemiology and Control</i> , 3 rd Evans, ed., A.S. Chapter 20:525-544 (1989)
C06	Chmura et al., <i>Proc. Natl. Acad. Sci. U.S.A.</i> (July 17, 2001) 98(15):8480-8484
C07	Foote et al., "Kinetic maturation of an immune response," <i>Nature</i> , Vol. 352:530-532 (8 August 1991)
C08	Garcia-Barreno, B. et al., "Marked Differences in the Antigenic Structure of Human Respiratory Syncytial Virus F and G Glycoproteins," <i>J. Virology</i> . 925-932 (1989).
C09	Heard et al., "Two Neutralizing Human Anti RSV Antibodies: Cloning, Expression and Characterization," <i>Molec. Med.</i> 5:35-45 (1999)
C10	Hefta et al., "Kinetic and affinity constants of epitope specific anti-carcinembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs," <i>Immunotechnology</i> 4:49-57 (1998)
C11	Hemming et al., "Immunoglobulins in respiratory syncytial virus infections," <i>Clinical Use of Intravenous Immunoglobulins</i> , Morell and Nydegger., eds., Academic Press, London, pp. 285-294 (1986)
C12	MedImmune, Inc., 1999, "SYNAGIS TM package insert", revised December 2, 1999
C13	MedImmune, SYNAGIS (registered trademark) package insert, revised Oct. 23, 2002.*
C14	Myszka et al., 1997, "Kinetic analysis of a protein antigen-antibody interaction limited by mass transport on an optical biosensor," <i>Biophysical Chem.</i> 64:127-137
C15	Orkin and Motulsky, "Report and recommendations of the panel to assess the NIH investment in research on gene therapy," available from http://www.nih.gov/news/panelrep.html (1995)
C16	Palomo, C. et al., "Induction of a Neutralizing Immune Response to Human Respiratory Syncytial Virus with Anti-Idiotypic Antibodies" <i>J. Virology</i> 64(9): 4199-4206 (1990)
C17	Roguska et al., "Humanization of murine monoclonal antibodies through variable domain resurfacing," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 91(3):969-973 (1994)
C18	U.S. Census Bureau, Age Data, website updated May 12, 2004, http://www.census.gov/population/www/socdemo/age.html
C19	U.S. Department of Commerce, Economics and Statistics Administration, Bureau of the Census, "We the American Elderly", Sep. 1993
C20	Verma et al., "Gene therapy - promises, problems and prospects," <i>Nature</i> 389:239-242 (1997)
C21	Wu et al., "Humanization of murine monoclonal antibody by simultaneous optimization of framework and CDR residues," <i>J. Mol. Biol.</i> 294(1): 151-62 (1999)
C22	Wu et al., "Ultra-potent Antibodies Against Respiratory Syncytial Virus: Effects of Binding Kinetics and binding Valence on Viral Neutralization," <i>J. Mol. Biol.</i> 350: 126-144 (2005)
C23	Yang et al., "CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range," <i>J. Mol. Biol.</i> 254:392-403, September 5, 1995

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.